Skip to main content

Prognostic Value of Patient Knowledge of Cancer on Quality of Life in Advanced Lung Cancer During Chemotherapy


The purpose of the study was to assess the impact of cancer knowledge and patient’s lifestyle on QOL and the relationship between QOL and various environmental factors in patients with non-small-cell lung cancer treated with chemotherapy. The study group consisted of 129 patients with metastatic lung cancer patients treated between May 2010 and December 2015 in two centres. The knowledge of cancer and their lifestyle was rated by method of diagnostic survey, using the Behavioral Health Inventory IZZ by Prof. Juczyński. We sought factors affecting to response to treatment, overall survival and quality of life. The general level of knowledge of cancer and the level of health behaviours was low. Ninety percent of lung cancer patients were smokers. The average age of the study group was 64 years. Eighty-nine patients received chemotherapy with cisplatin, 28 schemes containing carboplatin, 6 inhibitors of EGFR tyrosine kinase, and 6 vinorelbine or gemcitabine monotherapy. Complete regression was observed in 2 patients, partial response in 33 patients (26%), stable disease in 51 (40%) and 54 (42%) patients had progression. In multivariate analysis, significant effects on survival were performance status, schemes of treatment and response to treatment. Quality of life before and after treatment did not differ from each other. We found impact on quality of life: performance status, response to treatment and knowledge of cancer and lifestyle. The level of knowledge of oncological patients and their lifestyle observed in clinical practice are associated with QOL.

This is a preview of subscription content, access via your institution.



Non-small-cell lung carcinoma


Epidermal growth factor receptor


Anaplastic lymphoma kinase


Quality of life


Questionnaire Health Behaviour Inventory by Prof. Z. Juczyński


  1. 1.

    Ferlay J, Soerjomataram I, Ervik M et al GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, p 2013

  2. 2.

    Wojciechowska U, Didkowska J, Zatoński W (2012) Malignancies in Poland. The Maria Skłodowska-Curie Institute of Oncology, Warsaw

    Google Scholar 

  3. 3.

    De Angelis R, Sant M, Coleman MP et al (2014) Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5—a population-based study. Lancet Oncol 15:23–34

    Article  Google Scholar 

  4. 4.

    Cunningam D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after flurouracil failure for patients with metastatic colorectal cancer. Lancet 352:1407–1412

    Article  Google Scholar 

  5. 5.

    Aranda E, Valladares M, Martinez-Villacampa M et al (2009) Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish cooperative Group for the Treatment of digestive tumors study. Ann Oncol 20:251–257

    CAS  Article  Google Scholar 

  6. 6.

    The World Health Organization Quality of Life assessment (1995) (WHOQOL): position paper from the World Health Organization. Soc Sci Med 41:1403–1409

    Article  Google Scholar 

  7. 7.

    Adamowicz K, Zalewska M, Majkowicz M, Zaucha JM (2015) Evaluation of the impact of different types of health education on the adoption and preservation of Prohealth attitudes in preventing cancer in juveniles younger than 18 years. J Cancer Educ 30:432–438

    Article  Google Scholar 

  8. 8.

    Adamowicz K, Zaucha JM, Majkowicz M (2011) Assessment of the state of knowledge regarding cancer prevention among patients of the Breast Cancer Prevention Clinic Nowotwory. J Oncol 61:449–456

    Google Scholar 

  9. 9.

    Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343:905–914

    CAS  Article  Google Scholar 

  10. 10.

    Saad ED, Adamowicz K, Katz A, Jassem J (2012) Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials. Cancer Treat Rev 38:807–814

    Article  Google Scholar 

  11. 11.

    Adamowicz K, Jassem J, Katz A, Saad ED (2012) Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treat Rev 38:554–558

    Article  Google Scholar 

  12. 12.

    Hoon LS, Chi Sally CW, Hong-Gu H (2013) Effect of psychosocial intervene tions on outcomes of patients with colorectal cancer: a review of the literature. Eur J Oncol Nurs 17:883–891

    Article  Google Scholar 

  13. 13.

    Alacacioglu A, Binicier O, Gungor O et al (2010) Quality of life, anxiety, and depression in Turkish colorectal cancer patients. Support Care Cancer 18:417–421

    Article  Google Scholar 

Download references


Dr. Adamowicz is not currently in receipt of any research funding.

Author information




Krzysztof Adamowicz—contributed for the idea, data collection, data analysis and revision of the final text.

Justyna Janiszewska—interviewer, psychologist and interpretation of data.

Monika Lichodziejewska-Niemierko—content supervisor.

Corresponding author

Correspondence to Krzysztof Adamowicz.

Ethics declarations

Ethics Approval and Consent to Participate

Bioethical Commission at the District Chamber of Physicians in Gdansk.

Conflict of Interest

The author declares no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Adamowicz, K., Janiszewska, J. & Lichodziejewska-Niemierko, M. Prognostic Value of Patient Knowledge of Cancer on Quality of Life in Advanced Lung Cancer During Chemotherapy. J Canc Educ 35, 93–99 (2020).

Download citation


  • Lung cancer
  • Chemotherapy
  • Treatment outcomes
  • Quality of life
  • Knowledge of cancer